New Zealand markets closed

ABBV Jan 2023 97.500 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.0600-0.2100 (-16.54%)
As of 03:07PM EDT. Market open.
Full screen
Previous close1.2700
Open1.0600
Bid1.0300
Ask1.0900
Strike97.50
Expiry date2023-01-20
Day's range1.0600 - 1.0600
Contract rangeN/A
Volume1
Open interest2.06k
  • Zacks

    Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates

    The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).

  • Motley Fool

    Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip

    As prices go down, yields go up, and that dynamic has made both Target (NYSE: TGT) and AbbVie (NYSE: ABBV) excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks. For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble.

  • Zacks

    AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention

    With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.